Hot Features
Premium
Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AbCellera Biologics Inc | ABCL | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.63 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.63 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 3.62 - 8.05 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.63 | USD |
AbCellera Biologics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.05B | 289.36M | - | 38.03M | -146.4M | -0.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AbCellera Biologics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ABCL Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.85 | 4.31 | 3.62 | 3.86 | 1,415,480 | -0.22 | -5.71% |
| 1 Month | 4.54 | 4.7499 | 3.62 | 4.16 | 1,131,617 | -0.91 | -20.04% |
| 3 Months | 5.15 | 5.46 | 3.62 | 4.72 | 1,382,845 | -1.52 | -29.51% |
| 6 Months | 4.06 | 6.055 | 3.62 | 4.87 | 1,437,777 | -0.43 | -10.59% |
| 1 Year | 6.74 | 8.05 | 3.62 | 5.81 | 1,943,523 | -3.11 | -46.14% |
| 3 Years | 29.55 | 36.05 | 3.62 | 10.60 | 1,981,692 | -25.92 | -87.72% |
| 5 Years | 61.00 | 71.91 | 3.62 | 12.42 | 1,889,981 | -57.37 | -94.05% |
AbCellera Biologics Description
| AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners. |
